A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Launched by SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. · Mar 20, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The age of signing the informed consent is 18 -70 years, regardless of gender.
• • 2. At least one measurable lesion according to RECIST v1.1 criteria.
• • 3. The ECOG score is 0 or 1.
• • 4. Expected survival ≥12 weeks.
• • 5. Good level of organ function.
• • 6. Have the ability to give informed consent and to comply with the treatment plan.
• • 7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.
• Exclusion Criteria:
• • 1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.
• • 2. Spinal cord compression not cured by surgery and/or radiotherapy.
• • 3. Subjects with uncontrolled tumor-related pain.
• • 4. Received antitumor therapy within 4 weeks before the start of the study.
• • 5. Subjects with severe cardiovascular and cerebrovascular disease.
• • 6. History of immunodeficiency, including a positive HIV test.